Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Account Payables: 2021-2025

Historic Change in Account Payables for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to -$4.0 million.

  • Krystal Biotech's Change in Account Payables fell 4517.58% to -$4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $418,000, marking a year-over-year decrease of 69.71%. This contributed to the annual value of $1.0 million for FY2024, which is 1100.99% up from last year.
  • Per Krystal Biotech's latest filing, its Change in Account Payables stood at -$4.0 million for Q3 2025, which was down 197.50% from $4.1 million recorded in Q2 2025.
  • Krystal Biotech's Change in Account Payables' 5-year high stood at $4.1 million during Q2 2025, with a 5-year trough of -$4.0 million in Q3 2025.
  • For the 3-year period, Krystal Biotech's Change in Account Payables averaged around $174,455, with its median value being $107,000 (2023).
  • As far as peak fluctuations go, Krystal Biotech's Change in Account Payables skyrocketed by 579.44% in 2024, and later tumbled by 4,517.58% in 2025.
  • Krystal Biotech's Change in Account Payables (Quarterly) stood at $937,000 in 2021, then slumped by 200.11% to -$938,000 in 2022, then spiked by 76.33% to -$222,000 in 2023, then crashed by 166.22% to -$591,000 in 2024, then plummeted by 4,517.58% to -$4.0 million in 2025.
  • Its Change in Account Payables stands at -$4.0 million for Q3 2025, versus $4.1 million for Q2 2025 and $906,000 for Q1 2025.